Anti-aging Gene Therapy: Has The Time Arrived For True Anti-aging Medicine?

APRIL 24, 2016

Now in 2016 it is becoming increasingly clear that therapies are emerging which could seriously impact aspects of the human aging process.

One of the most cutting-edge therapies that are now being tested is the use of viral vectors to lengthen telomeres, the DNA caps at the end of our chromosomes. Elizabeth Parrish, CEO of the company Bioviva USA inc, is the first person to treat human aging with this technology, using herself as a test subject.

Contrary to much buzz within the anti-aging field, this is certainly a valid treatment for a part of the aging problem in organisms, by preventing DNA from shortening. Back in 2012 this experiment was first set up in mice by Maria Blasco et al, using adeno viruses to lengthen telomeres in mice. The treated mice lived longer on average with no increased cancer rates, showing proof of principle.


Human Gene Therapy Successfully Lengthens Telomeres

APRIL 23, 2016

In a bold and courageous move Elizabeth Parrish, CEO of Bioviva USA inc. became the first human to be treated with two gene therapies that her company has developed, one to lengthen her telomeres and one to prevent aging-related loss in muscle mass. With this move, she follows the footsteps of other courageous scientists, such as […]


Promising Results From The First Human Gene Therapy Against Aging

APRIL 22, 2016

The CEO of Bioviva USA Inc., Elizabeth Parrish, became the first person to undergo rejuvenative gene therapy in 2015, and results are now out – the procedure successfully lengthened her telomeres by the equivalent of 20 years.


First Gene Therapy Successful Against Human Aging

APRIL 21, 2016

In September 2015, then 44 year-old CEO of BioViva USA Inc. Elizabeth Parrish received two of her own company’s experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.

The treatment was originally intended to demonstrate the safety of the latest generation of the therapies. But if early data is accurate, it is already the world’s first successful example of telomere lengthening via gene therapy in a human individual. Gene therapy has been used to lengthen telomeres before in cultured cells and in mice, but never in a human patient.